Tetra Bio-Pharma Appoints New CEO

Tetra Bio-Pharma (CSE:TBP; OTCQB:TBPMF) appointed Bernard Fortier as new CEO, Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors.
As quoted in the press release:

Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a Board member.
Bernard Fortier is a graduate from the MBA program at l’école des Hautes Études Commerciales (HEC) in Montreal, with over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields.
Mr. Fortier spent 5 years in the USA working in the therapy and rehabilitation market, having graduated from the physiotherapy program at Laval University. His experience in the USA enabled him to work on business development and management early in his career. After completing his MBA in 2001, he joined the pharmaceutical industry with a biotechnology company. He spent 8 years in various key commercial roles at Serono Canada (now EMD Serono) in the Multiple Sclerosis field, including National Sales Manager for the Neurology business unit.

Click here to read the full press release.

Source: www.marketwired.com